Lumos Pharma Inc. | NLNK

Stock Price
3.75
Daily Change
2.18%
Yearly
-51.17%
Q2 Forecast
3.66
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agenus 1.59 0.03 1.60% -1.55%
Bristol-Myers Squibb 64.64 0.20 0.31% -13.89%
Capricor Therapeutics 4.60 0.07 1.44% 26.94%
Celldex Therapeutics 32.34 0.54 1.70% 41.10%
Aceragen 1.61 0.05 3.21% -87.02%
Incyte Corp 61.56 0.01 0.02% -17.51%
Eli Lilly 435.71 6.25 1.46% 44.07%
Merck & Co 110.79 0.38 0.34% 23.10%
Nektar Therapeutics 0.60 0.02 3.81% -83.55%
Lumos Pharma Inc. 3.75 0.08 2.18% -51.17%
Pfizer 37.98 -0.04 -0.11% -27.90%
Prothena 66.17 -0.27 -0.40% 147.62%
Sarepta Therapeutics 124.56 0.96 0.78% 71.62%
Vascular Biogenics 0.23 0.02 9.58% -85.98%
Intrexon 1.30 0.11 9.24% 7.44%

Indexes Price Day Year
USND 13073 138.20 1.07% 6.14%
US2000 1767 17.51 1.00% -6.88%

Lumos Pharma Inc.

Lumos Pharma Inc. traded at $3.75 this Thursday June 1st, increasing $0.08 or 2.18 percent since the previous trading session. Looking back, over the last four weeks, Lumos Pharma Inc. gained 17.19 percent. Over the last 12 months, its price fell by 51.17 percent. Looking ahead, we forecast Lumos Pharma Inc. to be priced at 3.66 by the end of this quarter and at 3.35 in one year, according to Trading Economics global macro models projections and analysts expectations.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.